An Observational Study of Chinese Adults with Relapsed/Refractory Philadelphia-Negative Acute Lymphoblastic Leukemia

Abstract

Aim:Chinese adults with relapsed/refractory Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia (Ph- ALL) have poor outcomes.Patients & methods:We conducted a nationwide, retrospective, observational study to assess outcomes in this patient population.Results:Of the 270 enrolled patients, 31% of patients at last salvage achieved complete remission (CR) or CR with partial hematologic recovery (CRh), with median time to CR/CRh of 30 days and median CR/CRh duration of 2.7 months. The CR/CRh rate was more favorable with earlier versus later lines of salvage (41, 24 and 17% at first, second and third or later salvages, respectively).Conclusion:This dataset serves as an important reference of real-world outcomes using currently available chemotherapy regimens for high-risk Chinese adults with relapsed/refractory Ph- ALL.

Welcome to Volume 8 of the International Journal of Hematologic Oncology

“…We have also published several original research articles; one of our highlights is from the Harbin Institute of Hematology & Oncology (China), which provides an observational study of Chinese adults with relapsed/refractory Philadelphia-negative acute lymphoblastic leukemia [3]. This form of leukemia often has a poor outcome in this population group so this study from Ma et al could help in providing reference material when determining the course of treatment.…”

A pediatric-inspired regimen for adolescent and adult patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a prospective study from China

“…Moreover, there is a lack of prospective data on the efficacy and safety of pediatric-inspired regimens in adolescent and adult patients with Ph -ALL in China. 9,10 Herein, we present our single-center prospective data on a pediatric-inspired regimen (IH-2014 regimen) for treating patients aged 14-65 years with Ph -ALL. The primary objective of the present study was to assess the efficacy and safety of a pediatric-inspired regimen and to explore the prognostic significance of minimal residual disease (MRD) combined with traditional risk factors.…”